A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
about
MET molecular mechanisms and therapies in lung cancerAlternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancerA Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity PredictionHepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathwayCharacterization of novel synthesized small molecular compounds against non-small cell lung cancer.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsImmunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.Effects of high intensity training and high volume training on endothelial microparticles and angiogenic growth factorsMET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesAnti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cellsOverexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621High-throughput mutational analysis of the human cancer genome.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Expression and mutational analysis of MET in human solid cancersDisruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivityc-Met targeted therapy of cholangiocarcinomaDirected discovery of agents targeting the Met tyrosine kinase domain by virtual screeningMET as a target for treatment of chest tumorsSimm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.Everolimus induces Met inactivation by disrupting the FKBP12/Met complexMET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.Advances in preclinical small molecules for the treatment of NSCLC.Special issue: "MET as actionable target in cancer therapy".MET targeted therapy for lung cancer: clinical development and future directionsSelection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Genetics of medulloblastoma: clues for novel therapies.Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.Targeting the Met pathway in lung cancer.Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.Emerging Role of MicroRNAs in mTOR Signaling.Future directions in the evaluation of c-MET-driven malignancies.PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
P2860
Q28272688-267E1731-55E4-4BC5-8C9D-B5D27A4BC245Q28534819-29B2F394-077D-434D-9391-C4C0A7BF4E2CQ28551596-5386B422-9EF5-41FA-ACCF-D800DE25D1B8Q28570356-57C2A548-06DB-47C3-9662-46B62384E307Q30429640-B8809B1A-64B8-4593-BEDE-6C8B72E83353Q30502341-61BD4AB6-CF70-4C21-A0E7-AFD87406395EQ33556731-C876E473-37EC-4D95-B607-A63B4BD65DA3Q33756853-F0DDDD75-867C-4B3C-B15C-036398F48761Q34701196-A9BB1164-9CBB-4F62-9A95-D8ED0C8C7711Q35146937-A51006AC-CDF7-4CA5-9AD0-CBED1117F026Q35158221-5966E835-FBB0-473A-A373-0E0CD305FF8FQ35208173-6A4404B1-1359-449D-9878-93AD29471931Q35924247-A2518B55-2168-41DB-BBFF-9386C0CAE929Q36090650-2EA47DC4-4D11-4C77-B37D-10CB3546EAFBQ36213128-5959FAED-BEB0-49F1-9733-00FBBDB9A89FQ36291482-84710B26-E375-4477-B8FD-505676407455Q36411841-68839D5F-C28E-43A6-AC3B-EB9CCC731BC0Q36497083-C246AC53-76BF-468A-9E2B-DB1AA0B67850Q36742629-BA437556-9CB5-449A-B336-8F4C01BE9ECBQ36882696-7688FEAD-C2C4-4ACE-B0E7-820590E0B4FDQ36975055-9B079112-2508-4683-8F9E-3035E2B8F975Q37078736-585960CF-4444-45BE-A0D6-82743D290846Q37169357-57E3E97F-F71F-4DCA-97EC-A72DC14FD581Q37231567-F6E48068-F87E-41D0-9F2D-643CDC1F8F59Q37232416-CA4DAD33-2647-4D28-89FB-EB4D028D3E9FQ37437415-B1BD83C4-E5D5-4164-AB14-333CB61E7913Q37457794-35B80733-73F2-462C-B869-9F0D5AEC5E03Q37470505-6EADC42F-8040-457E-AAB4-A6667401C8BBQ37489942-FAD662F1-9408-4312-BF86-A1413273FD06Q37597847-998119D1-1A7A-4278-9589-92F382BF8D2BQ37645240-021EC5EE-FEC7-4E43-AB05-C921379CD104Q37730020-8D1612BB-510E-4FD6-A148-B26279E68A51Q37737307-C1739FD3-19EC-493C-A9BB-405A274CDFB1Q37836508-B974D323-85E9-44BE-9FB9-BB55C35AD54DQ38002473-DB003ADA-96F9-4440-9E76-BF31364B6C33Q38694303-034D08FE-77D6-45DB-B6CC-0C5E98BCFF31Q39151248-F9D20961-2B45-44F1-A901-4FF3920902B0Q39405818-7C1562D9-C3D9-4364-9C6E-DBFF7D307A3BQ39896091-B462C106-92D8-41F1-86AE-4A9CB09D2976Q39991720-EBF1F322-DF7A-4554-95BC-D877BC476A12
P2860
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@en
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@nl
type
label
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@en
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@nl
prefLabel
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@en
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@nl
P2093
P1476
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
@en
P2093
Erik Schaefer
James G Christensen
Patrick C Ma
P304
P356
10.1158/1078-0432.CCR-04-1708
P407
P50
P577
2005-03-01T00:00:00Z